OTR3

OTR3 is a French biotech company that has developed a new class of therapeutic agents used for skin and corneal healing. The therapeutic approach, called Matrix therapy is based on RGTA (ReGeneraTing Agents), engineered biodegradable sugar-based nano-polymers, mimicking heparan-sulfates. After an injury, RGTA target the wound, replace the degradated heparan-sulfates, bind to the proteins and growth factors and protect the matrix proteins from degradation. They restore the scaffold organization and the micro-environment of the cells allowing the tissue to rebuild. OTR3 has placed on the market medical devices indicated for the treatment of hard to heal chronic cutaneous ulcers and...

Matrix therapy,healing,regenerating agents,rgta®,chronic wounds,corneal lesions,cacipliq20®,cacicol20®,regenerative medicine,ischemic stroke,and ards

Otr3 operates in the Biotechnology industry.

Otr3's revenue is 11m - 100m

Otr3 has 11 - 50 employees.